** Amplia Therapeutics ATX.AX slips as much as 14% to A$0.245, lowest since July 4
** Stock marks biggest intraday pct drop since June 30
** Drug developer announces capital raise of A$27.5 mln ($18 mln) at issue price of A$0.23, representing 19.3% discount to last close
** Says funds will support ACCENT and AMPLICITY trials, support ovarian cancer trials of co's lead drug, narmafotinib (AMP945
** Stock last down 10.5%, trims YTD gains to ~192%
($1 = A$1.5253)
(Reporting by Anjali Singh in Bengaluru)
((anjali.singh2@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.